Pavel, Marianne
Borson-Chazot, Françoise
Cailleux, Anne
Hörsch, Dieter
Lahner, Harald
Pivonello, Rosario
Tauchmanova, Libuse
Darstein, Christelle
Olsson, Håkan
Tiberg, Fredrik
Ferone, Diego
Funding for this research was provided by:
Camurus in collaboration with Novartis Pharma AG.
Article History
Received: 2 August 2018
Accepted: 23 November 2018
First Online: 8 December 2018
Compliance with ethical standards
:
: MP received honoraria for presentations or advisory board from Novartis, IPSEN, Pfizer, and Lexicon. AC has nothing to disclose. FBC received consulting fees for advisory board from Novartis, Ipsen, Merck Serono, Bayer, and Pfizer; honorarium for speaking from Bayer, HAC, and Genzyme. DH received personal fees from Lexicon Pharma, grants and personal fees from Ipsen Pharma Inc, during the conduct of the study; personal fees from Lexicon Pharma Inc; grants and personal fees from Ipsen Pharma Inc, Novartis Pharma Inc, and Pfizer Pharma Inc, outside the submitted work. HL received consulting fees from Novartis. RP received research grant as principal investigator and co-investigator, and lecturer fee and honoraria from Novartis; research grant as clinical researcher, consulting fees, and honoraria as speaker from Shire; research grant as principal investigator from Ipsen and Pfizer. LT and CD are employees of Novartis. HO and FT are employees of Camurus. DF received consulting fee for lectures or advisory boards, and research funding for preclinical research project from Novartis; received consulting fee for advisory boards, and research funding for preclinical research project from Ipsen.
: The study was conducted in accordance with the Declaration of Helsinki and applicable local regulations. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. All patients provided written informed consent to participate in the study.